2024
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024
C K, Surie D, Lauring A, Martin E, Leis A, Papalambros L, Gaglani M, Columbus C, Gottlieb R, Ghamande S, Peltan I, Brown S, Ginde A, Mohr N, Gibbs K, Hager D, Saeed S, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Hough C, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Parikh B, Exline M, Vaughn I, Ramesh M, Safdar B, Mosier J, Harris E, Shapiro N, Felzer J, Zhu Y, Grijalva C, Halasa N, Chappell J, Womack K, Rhoads J, Baughman A, Swan S, Johnson C, Rice T, Casey J, Blair P, Han J, Ellington S, Lewis N, Thornburg N, Paden C, Atherton L, Self W, Dawood F, DeCuir J. Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024. Clinical Infectious Diseases 2024, ciae405. PMID: 39107255, DOI: 10.1093/cid/ciae405.Peer-Reviewed Original ResearchInvasive mechanical ventilationIntensive care unitCase-patientsOdds of severe outcomesCOVID-19 vaccineLogistic regressionOdds of ICU admissionCOVID-19 vaccine dosesControl-patientsAnalyzed patientsImmune escapeCase-control designVaccine compositionMechanical ventilationClinical severityICU admissionVaccine doseCare unitTest-negativeVaccine effectivenessSevere outcomesCOVID-19-like illnessCOVID-19 vaccine effectivenessSARS-CoV-2Hospital
2023
2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023
DeCuir J, Zhu Y, Gaglani M, Ginde A, Mohr N, Gibbs K, Hager D, Frosch A, Mohamed A, Johnson N, Steingrub J, Peltan I, Martin E, Bender W, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Lauring A, Columbus C, Vaughn I, Safdar B, Chappell J, Baughman A, Womack K, Swan S, McMorrow M, Self W, Surie D. 2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023. Open Forum Infectious Diseases 2023, 10: ofad500.153. PMCID: PMC10677158, DOI: 10.1093/ofid/ofad500.153.Peer-Reviewed Original ResearchCOVID-19-associated hospitalizationRelative vaccine effectivenessVaccine effectivenessBooster doseSARS-CoV-2Hospitalized adultsIllness onsetDays of receiptCOVID-19 vaccination seriesCOVID-19-like illnessAdditional booster dosesAsahi Kasei PharmaMRNA vaccine effectivenessMultivariable logistic regressionHuman Services (HHS) regionsCase-control analysisUnvaccinated patientsVaccination seriesBooster dosesImmunization PracticesMRNA vaccinationAdults AgedRespiratory virusesAntigen testAdmission date